These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20509268)

  • 41. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
    Berger DS
    Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
    [No Abstract]   [Full Text] [Related]  

  • 44. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
    Delaugerre C; Roudiere L; Peytavin G; Rouzioux C; Viard JP; Chaix ML
    J Clin Virol; 2005 Mar; 32(3):241-4. PubMed ID: 15722030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
    Van Laethem K; De Munter P; Schrooten Y; Verbesselt R; Van Ranst M; Van Wijngaerden E; Vandamme AM
    J Clin Virol; 2007 May; 39(1):43-7. PubMed ID: 17369083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atazanavir sulphate.
    Raja A; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Nov; 2(11):857-8. PubMed ID: 14702957
    [No Abstract]   [Full Text] [Related]  

  • 55. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 56. Dupont data supports earlier findings.
    Slovick J
    Posit Living; 1999 Nov; 8(10):45. PubMed ID: 11367331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The new drugs and how to use them.
    Gallant JE
    Hopkins HIV Rep; 1999 Jan; 11(1):2, 7. PubMed ID: 11366160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
    van Leth F; Prins JM; Lange JM; Geerlings SE
    AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059
    [No Abstract]   [Full Text] [Related]  

  • 59. CRIA clinical trials.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():59. PubMed ID: 11367496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Simple, safe and effective. New protease inhibitor means progress].
    MMW Fortschr Med; 2002 Dec; 144(49):52-3. PubMed ID: 12577744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.